Supportive analysis of an independent cohort of CRC patients using cBioPortal of Cancer Genomics [Colorectal Adenocarcinoma, TCGA, Provisional, n = 633] (Supplementary Table S5 and S9) evinced that TUSC3 gene alterations, mainly deletions and missense mutations, conferred poor clinical outcome when combined with those in ErbB receptors, indicative of a possible cooperation of these pathways as proposed from our experiments in CRC cell lines. The gene discussed is TUSC3; the disease is colorectal carcinoma.